Sagimet Biosciences announced a global, exclusive license agreement with TAPI for innovative forms of resmetirom API.
The collaboration supports Sagimet's fixed-dose combination program in clinical development.
Topline data from Sagimet's Phase 1 trial of denifanstat and resmetirom is expected by the end of 2025.
Exclusive License Agreement
Sagimet granted global, exclusive license to TAPI's innovative forms of resmetirom API.
Clinical Development Support
License agreement supports Sagimet's FDC program with denifanstat and resmetirom.
Phase 1 Trial Progress
Anticipated top-line data from Phase 1 trial of denifanstat and resmetirom by end of 2025.
- The license agreement with TAPI provides a pathway for developing a synergistic combination therapy for MASH patients with cirrhosis of the liver.
- Sagimet's innovative forms of resmetirom offer potential improvements in clinical outcomes for patients with limited treatment options.
The collaboration between Sagimet and TAPI opens new possibilities for developing effective treatments for metabolic and fibrotic diseases, with a focus on cirrhosis of the liver. This agreement marks a significant step towards addressing the unmet medical needs in the field of metabolic dysfunction.